EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLL.

by Romana Ruiss, Simon Jochum, Ralph Mocikat, Wolfgang Hammerschmidt, Reinhard Zeidler
Published 2011-01-01

The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

by Simon Jochum, Andreas Moosmann, Stephan Lang, Wolfgang Hammerschmidt, Reinhard Zeidler
Published 2012-01-01